JP2021517168A5 - - Google Patents

Info

Publication number
JP2021517168A5
JP2021517168A5 JP2020571336A JP2020571336A JP2021517168A5 JP 2021517168 A5 JP2021517168 A5 JP 2021517168A5 JP 2020571336 A JP2020571336 A JP 2020571336A JP 2020571336 A JP2020571336 A JP 2020571336A JP 2021517168 A5 JP2021517168 A5 JP 2021517168A5
Authority
JP
Japan
Prior art keywords
acid sequence
composition according
gba
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020571336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517168A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/021422 external-priority patent/WO2019173756A1/en
Publication of JP2021517168A publication Critical patent/JP2021517168A/ja
Publication of JP2021517168A5 publication Critical patent/JP2021517168A5/ja
Priority to JP2024075599A priority Critical patent/JP2024102250A/ja
Pending legal-status Critical Current

Links

JP2020571336A 2018-03-09 2019-03-08 パーキンソン病を処置するための組成物及び方法 Pending JP2021517168A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024075599A JP2024102250A (ja) 2018-03-09 2024-05-08 パーキンソン病を処置するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862641012P 2018-03-09 2018-03-09
US62/641,012 2018-03-09
PCT/US2019/021422 WO2019173756A1 (en) 2018-03-09 2019-03-08 Compositions and methods for treating parkinson's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024075599A Division JP2024102250A (ja) 2018-03-09 2024-05-08 パーキンソン病を処置するための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2021517168A JP2021517168A (ja) 2021-07-15
JP2021517168A5 true JP2021517168A5 (https=) 2022-03-15

Family

ID=67847471

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571336A Pending JP2021517168A (ja) 2018-03-09 2019-03-08 パーキンソン病を処置するための組成物及び方法
JP2024075599A Pending JP2024102250A (ja) 2018-03-09 2024-05-08 パーキンソン病を処置するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024075599A Pending JP2024102250A (ja) 2018-03-09 2024-05-08 パーキンソン病を処置するための組成物及び方法

Country Status (8)

Country Link
US (1) US20210000929A1 (https=)
EP (1) EP3762505A4 (https=)
JP (2) JP2021517168A (https=)
AU (2) AU2019231889A1 (https=)
CA (1) CA3092961A1 (https=)
IL (1) IL277182A (https=)
MA (1) MA54792A (https=)
WO (1) WO2019173756A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115087455A (zh) * 2019-11-12 2022-09-20 奥查德疗法(欧洲)有限公司 用于治疗或预防克罗恩病的组合物和方法
CN115348884B (zh) * 2020-03-29 2024-07-30 耶达研究及发展有限公司 用于治疗戈谢病的β-葡糖脑苷脂酶变体
EP4146797A1 (en) * 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
US20230227847A1 (en) * 2020-05-27 2023-07-20 Universität Zürich Viral vectors expressing therapeutic proteins specifically in myeloid cells and microglia
BR112023001456A2 (pt) * 2020-07-27 2023-04-11 Voyager Therapeutics Inc Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
WO2023004366A1 (en) * 2021-07-21 2023-01-26 Aspen Neuroscience, Inc. Transposon-based modulation of gba1 and related compositions and uses thereof
JP2026506873A (ja) * 2023-02-02 2026-02-27 エンボールド セラピューティクス, インコーポレイテッド 操作されたグルコセレブロシダーゼバリアント
WO2024238448A2 (en) * 2023-05-12 2024-11-21 Temple University - Of The Commonwealth System Of Higher Education Chimeric capsid recombinant adeno-associated virus with bbb penetration and microglia targeting (aav-bm)
GB202307366D0 (en) * 2023-05-17 2023-06-28 Ospedale San Raffaele Srl Vector
US12565639B2 (en) 2023-06-13 2026-03-03 Aspen Neuroscience, Inc. Methods for differentiating dopaminergic neurons from stem cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2215222T3 (es) * 1996-12-05 2004-10-01 Crucell Holland B.V. Modificacion genetica de celulas cepa de repoblacion hematopoyeticas de primates.
AU2006254796B2 (en) * 2005-06-08 2012-08-16 Amicus Therapeutics, Inc. Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes
MY161859A (en) * 2011-01-03 2017-05-15 Avm Biotechnology Llc Personalized production of biologics and method for reprogramming somatic cells
EP3196301B1 (en) * 2012-07-11 2018-10-17 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of monogenic diseases
ES2729997T3 (es) * 2012-11-27 2019-11-07 Biomarin Pharm Inc Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
CA2985235A1 (en) * 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
US20190085394A1 (en) * 2015-12-14 2019-03-21 Parkinson's Institute Refining diagnosis and treatment of complex multi-symptom neurological disorders
GB201522243D0 (en) * 2015-12-16 2016-01-27 Ucl Business Plc Treatment
BR112020008033A2 (pt) * 2017-10-23 2020-10-27 Prevail Therapeutics, Inc. terapias gênicas para doença neurodegenerativa

Similar Documents

Publication Publication Date Title
JP2021517168A5 (https=)
EP3198018B1 (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
EP2500434A1 (en) Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
JP2022523913A5 (https=)
EP2691529B1 (en) AAV2 particle comprising an AAV2 capsid protein and a vector comprising a nucleic acid encoding a tripeptidyl peptidase 1 (TPP1) for use in treating late infantile ceroid lipofuscinosis (LINCL) in a non-rodent mammal by intraventricular injection or ICV delivery.
US12600986B2 (en) Nucleic acid molecules containing spacers and methods of use thereof
JP2024102250A (ja) パーキンソン病を処置するための組成物及び方法
JP2025069281A (ja) 調節可能な発現系
CN113557243A (zh) 用于神经变性疾病的基因疗法
WO2022166954A1 (en) Rna adeno-associated virus (raav) vector and uses thereof
KR20240164824A (ko) 조작된 소형 핵 rna(snrna)를 포함하는 조성물 및 방법
CN113302291A (zh) 使用逆转录病毒整合酶-Cas9融合蛋白通过定向非同源DNA插入进行的基因组编辑
US20240026381A1 (en) Split prime editing platforms
CN120548368A (zh) 用于正确包装重复元件的腺相关病毒载体
JP2022523123A5 (https=)
WO2024050547A2 (en) Compact bidirectional promoters for gene expression
KR20250006887A (ko) 간에서 유전자 발현의 탈표적화를 위한 요소
WO2023147558A2 (en) Crispr methods for correcting bag3 gene mutations in vivo
JP2024515715A (ja) レトロウイルスインテグラーゼ-Cas融合タンパク質を使用した指向性非相同DNA挿入によるゲノム編集及び治療の方法
CN116917471A (zh) 溶酶体酸性脂肪酶变体及其用途
US20250381303A1 (en) Crispr interference therapeutics for c9orf72 repeat expansion disease
JP2024504422A (ja) Aavに基づく遺伝子発現の調節
WO2025094056A1 (en) Gene therapy constructs and methods of use therefor
CA3140507A1 (en) Insulin gene therapy
HK1240977B (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof